The Latest Cardiac and Vascular News
SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ — Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as “Ribo”) today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive…
Collaboration combines Evogene’s AI-driven computational chemistry platform with ELEO’s proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar cardiovascular market opportunity REHOVOT, Israel and DAEJEON, South Korea, July…
WALTHAM, Mass.–(BUSINESS WIRE)–Affinia Therapeutics (“Affinia”), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for AFTX-201 for the treatment of BAG3-associated dilated cardiomyopathy (DCM). A potential best-in-class investigational genetic m
Powered by retrospective real-world data from Dandelion Health, the American Heart Association’s AI Impact Report provides a third-party evaluation of Ultromics’ EchoGo® Heart Failure The independent assessment shows EchoGo® Heart Failure could have identified HFpEF 263 days earlier than…
SEATTLE & YOKNEAM, Israel–(BUSINESS WIRE)– #DRIVEWIRE–Rapid Medical FDA-cleared DRIVEWIRE 35, first steerable 0.035-inch guidewire for stroke, neurovascular and peripheral access, after 5,000 DW24 cases.
BOTHELL, Wash.–(BUSINESS WIRE)–FUJIFILM Sonosite, Inc., a global leader in point-of-care ultrasound (POCUS) solutions, today announced the launch of Sonosite iLOOK, a compact ultrasound solution designed specifically for vascular access. Sonosite iLOOK combines a purpose-built user interface, wireless transducer technology, and flexible mounting options in a streamlined solution intended to support vascular access procedures at the bedside Developed specifically for vascular access workflows,
ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 second quarter on Tuesday, August 11, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.
Proceeds will be used to advance the company’s AI-native cardiovascular platform and expand partnerships with health plans and cardiology practices nationwide ALBUQUERQUE, N.M., July 21, 2026 /PRNewswire/ — Karoo Health, a cardiovascular technology company building an operating system…
NATURE trial, a prospective randomized controlled trial comparing the safety and effectiveness of thrombectomy using enVast before conventional PCI versus standard of care alone, was selected for the prestigious Late-Breaking Clinical Trials session at the European Society of Cardiology…
Route 92 Medical celebrates the 200th patent for its neurovascular intervention portfolio.
